Hydrochlorothiazide and atenolol combination antihypertensive therapy: Effects of drug initiation order

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 5, 2009, Pages 533-539

  Johnson, J A ^a,b,c   Gong, Y ^a   Bailey, K R ^d   Cooper Dehoff, R M ^a,b,c   Chapman, A B ^e   Turner, S T ^d   Schwartz, G L ^d   Campbell, K ^b,c   Schmidt, S ^b,c   Beitelshees, A L ^f   Boerwinkle, E ^g   Gums, J G ^a,b,c  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d Mayo Clinic   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; HYDROCHLOROTHIAZIDE;

ADD ON THERAPY; ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CAUCASIAN; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NEGRO; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BLOOD PRESSURE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED;

EID: 70350231396     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.101     Document Type: Article

References (15)

1. American Heart Association. Heart Disease and Stroke Statistics-2008 Update (American Heart Association, Dallas, TX, 2008). Accessed 18 June 2008.
2. Chobanian, A.V. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289, 2560-2571 (2003).
3. Houston, M.C. ALLHAT debate: diuretics are not preferred, frst-line initial therapy for hypertension. Arch. Intern. Med. 164, 570-571 (2004); author reply 571-572.
4. Scott, I. & Stowasser, M. Are thiazide diuretics preferred as frst-line therapy for hypertension? An appraisal of The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Intern. Med. J. 33, 327-330 (2003).
5. Sica, D.A. Diuretics should continue to be one of the preferred initial therapies in the management of hypertension: the argument against. J. Clin. Hypertens. (Greenwich) 7, 117-120 (2005); quiz 121-1112
6. Ernsberger, P. & Koletsky, R.J. Metabolic efects of antihypertensive agents: role of sympathoadrenal and renin-angiotensin systems. Naunyn Schmiedebergs Arch. Pharmacol. 373, 245-258 (2006).
7. Pickering, T.G. et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 111, 697-716 (2005).
8. ALLHAT Ofcers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288, 2981-2997 (2002).
9. Dahlöf, B. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrofumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366, 895-906 (2005).
10. Weber, M.A. et al. Blood pressure dependent and independent efects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 363, 2049-2051 (2004).
11. Johnson, J.A. et al. Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am. Heart J. 157, 442-449 (2009).
12. O'Brien, E., Waeber, B., Parati, G., Staessen, J. & Myers, M.G. Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ 322, 531-536 (2001).
13. Ohkubo, T. et al. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J. Hypertens. 16, 971-975 (1998).
14. Stergiou, G.S. et al. Reproducibility of home, ambulatory, and clinic blood pressure: implications for the design of trials for the assessment of antihypertensive drug efcacy. Am. J. Hypertens. 15, 101-104 (2002).
15. Imai, Y. et al. Usefulness of home blood pressure measurements in assessing the efect of treatment in a single-blind placebo-controlled open trial. J. Hypertens. 19, 179-185 (2001).